9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed

Estimated reading time: < 1 min

Condition: Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy

Estimated Enrollment: 200

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Association between PPI consumption and pemetrexed-related hematological toxicity (grade ≥ 3),  ,  ,

Interventions: pemetrexed-related hematological toxicity,

Phase:

Study Type: Observational

Study Design: Observational Model: Cohort, Time Perspective: Prospective, ,

Primary Completion Date: November 2, 2020

Completion Date: May 2, 2022

Last  Posted Date: May 30, 2019

Location: Chu Reims, Reims, France

Website Link: https://ClinicalTrials.gov/show/NCT03537833

Was this article helpful?
Dislike 0